These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2189906)
1. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. Degreef H; Dockx P; De Doncker P; De Beule K; Cauwenbergh G J Am Acad Dermatol; 1990 May; 22(5 Pt 1):751-5. PubMed ID: 2189906 [TBL] [Abstract][Full Text] [Related]
2. Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. Black AK; Camp RD; Mallet AI; Cunningham FM; Hofbauer M; Greaves MW J Invest Dermatol; 1990 Jul; 95(1):50-4. PubMed ID: 2164070 [TBL] [Abstract][Full Text] [Related]
3. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. Bernhard J; Whitmore C; Guzzo C; Kantor I; Kalb RE; Ellis C; Urbach F; Schwartzel EH; Gibson JR J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1170-4. PubMed ID: 1757612 [TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614 [TBL] [Abstract][Full Text] [Related]
6. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. van de Kerkhof PC; van Pelt H; Lucker GP; Steijlen PM; Heremans A Skin Pharmacol; 1996; 9(5):307-11. PubMed ID: 8990505 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M; Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Guenther L; Van de Kerkhof PC; Snellman E; Kragballe K; Chu AC; Tegner E; Garcia-Diez A; Springborg J Br J Dermatol; 2002 Aug; 147(2):316-23. PubMed ID: 12174105 [TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. Feldman SR; Mills M; Brundage T; Eastman WJ J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912 [TBL] [Abstract][Full Text] [Related]
10. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Mrowietz U; Wustlich S; Hoexter G; Graeber M; Bräutigam M; Luger T Acta Derm Venereol; 2003; 83(5):351-3. PubMed ID: 14609102 [TBL] [Abstract][Full Text] [Related]
11. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis. Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619 [TBL] [Abstract][Full Text] [Related]
12. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial. Li N; Zhao W; Xing J; Liu J; Zhang G; Zhang Y; Li Y; Liu W; Shi F; Bai Y BMC Complement Altern Med; 2017 May; 17(1):264. PubMed ID: 28506228 [TBL] [Abstract][Full Text] [Related]